Orifarm delivers record results and sets new growth trajectory

"2025 marks the strongest performance in Orifarm’s history, driven by major leaps in both free cash flow and profitability alongside strong commercial momentum. This exceptional progress is a pivotal moment in Orifarm’s strategic transformation. It shows that our efforts to create a more efficient, profitable and scalable business are delivering exactly the impact we aimed for,” says CEO Mads Fink Eriksen, who assumed office in May last year. 

“This breakthrough year puts Orifarm on a stronger path for future growth. This year, we will continue to build on our momentum with the same disciplined approach, so we can provide access to affordable, high-quality medicine to even more people across Europe.” 

Commercial highlights 
Revenue grew by 11%, exceeding expectations to reach an all-time high of €2 billion, fueled by stronger commercial performance across all business segments including record levels in several markets. Pharma Trade increased revenue by 12% in yet another strong year, solidifying Orifarm’s position as Europe's largest parallel importer of pharmaceuticals, while Specialty Rx grew by 7% and Consumer Healthcare by 6%.   

In 2025, Orifarm took significant steps to expand its global footprint and portfolio to bring more societal savings to more markets. Key commercial highlights include launching Specialty Rx products in Germany, UK and Holland, building on spearhead consumer brands with the launch of Ibumetin® Express in several markets, and launching more than 900 products in the company’s Pharma Trade business.

Progress on strategic priorities  
Revenue growth combined with stronger cost management delivered a 12% increase in EBITDA to €153.8m and a 39% increase in operating profit, reaching a record-high of €96.5 million. At the same time, Orifarm significantly improved earnings before tax and generated a record-high free cash flow of €183.7 million.  

In addition to operational efficiency initiatives, Orifarm established an office in Warsaw, Poland, as part of steps to strengthen scalability. 

“In 2025, we made a step-change in our free cash flow, enabling us to increase our financial flexibility and resilience in an increasingly competitive market. These results are the direct outcome of initiatives introduced early in the year to increase operating discipline: a sharper focus on prioritization, cost control, and scalability. I am immensely proud of our employees’ commitment to these initiatives while delivering value for patients, customers and healthcare systems across Europe,” says Mads Fink Eriksen.  

Orifarm strengthened its executive leadership team last year to support the next stage of its growth journey. In addition to a new CEO, Orifarm appointed a new Chief Financial Officer, Chief Information Officer, and Chief Business Development and Portfolio Strategy Officer.  

Looking ahead, Orifarm will continue its focus on profitable growth and expand its presence in Europe. Strategic priorities for 2026 include market entry in Italy, digitalization investments, and continued pursuit of both organic and inorganic growth opportunities. 

2025 financial highlights 

• Revenue grew by 11%, reaching €2bn, the highest turnover in the company’s history (2024: €1.8bn)  

• Product portfolio delivered strong commercial performance fuelled by 12% growth in the Pharma Trade segment, 7% growth in Specialty Rx and 6% in Consumer Healthcare

• Operating profit increased by 39% to a record-high of €96.5m (2024: €69.5m)

• Free cash flow reached a record-high of €183.7m (2024: €40.6m)

• EBITDA increased by 12% to €153.8m (2024: €136.8m)